# MAIA Biotechnology

MAIA Biotechnology is an Asset Manager based in Chicago, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Chicago, United States
- **Region:** North America
- **Address:** Chicago, IL, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** maiabiotech.com
- **LinkedIn:** https://www.linkedin.com/company/maiabiotech

## Regulatory record

- **Reports private funds:** No

## About

MAIA Biotechnology is a targeted therapy, immuno-oncology company focused on development of first-in-class drugs | MAIA Biotechnology is a targeted therapy, immune-oncology company, focused on development and commercialization of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.

## Sectors

- Digital Health
- Healthcare Services

## People

- Vlad Vitoc — Chief Executive Officer

## Questions

### Who runs investment decisions at MAIA Biotechnology?

MAIA Biotechnology is an operating biopharmaceutical company, not an investment firm. Capital allocation decisions rest with CEO Vlad Vitoc and the board of directors, who oversee the public company's budget and clinical-trial financing strategy. The firm's spending is directed almost entirely toward R&D, with no external fund commitments or LP-driven investment mandates.

### How does MAIA Biotechnology source its deal flow or pipeline assets?

MAIA does not source deals in the traditional investment sense; its pipeline originates from in-house research into telomere-targeting mechanisms. The company's scientific team identifies and validates new chemical entities targeting telomerase, filing its own patents and advancing leads toward Investigational New Drug applications. Occasional in-licensing of complementary technologies supplements the internal discovery engine.

### What investment stages or asset classes does MAIA target?

MAIA is not an investment manager and does not deploy capital into fund commitments, direct co-investments, or real assets. The firm's balance sheet is allocated to clinical development, manufacturing, and intellectual property related to its oncology programs. External collaborations are structured as research agreements rather than financial investments.

### Where does MAIA Biotechnology's funding come from?

Funding comes from public equity raises, including its 2022 initial public offering and subsequent at-the-market facilities, supplemented by National Cancer Institute grants and potential licensing revenue. The company has not disclosed backing from a single-family source or sovereign wealth entity, distinguishing it from privately capitalized family office biotech ventures.

## Related profiles

- [5E Advanced Materials](https://altss.com/profile/5e-advanced-materials-inc)
- [First Seacoast Bancorp](https://altss.com/profile/first-seacoast-bancorp-inc)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/maia-biotechnology-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology